SBIR Phase I: RAPID Integrated and automated genomics platform for hospitals responding to COVID-19

SBIR 第一阶段：用于医院应对 COVID-19 的 RAPID 集成自动化基因组学平台

• 批准号: 2027424
• 负责人: Susanna Lamers
• 金额: $ 25.6万
• 依托单位: Bioinfoexperts, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2027424&HistoricalAwards=false
• 关键词: SBIR; Phase; RAPID; Integrated; automated

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project will be a user-friendly and scalable infection control surveillance software platform using advanced biotech and data analytics for monitoring the COVID-19 pandemic. The COVID-19 pandemic highlights the need for rapid testing, analysis, and tracking. The innovation provides access to next-generation sequence technologies to healthcare facilities, as well as a centralized system to integrate and share hospital-level data with microbial information to be shared on any geographic scale. The platform automates the analysis of bacterial and viral data, delivering simplified and clinically relevant results via interactive web interfaces. The proposed technology offers important data to clinicians and other experts. The intellectual merit of this SBIR Phase I project is to generate the largest collection of SARS-CoV-2 whole genomes with matched respiratory microbiomes for clinicians to rapidly test medical hypotheses for diagnostic and prescriptive use. Our project has three major objectives: 1) incorporate an automated analytical pipeline to process whole genomes of infecting strains of SARS-CoV-2; 2) integrate viral genomes with patient microbiomes and clinical records, and; 3) deliver clear, easy-to-interpret results via an interactive web interface. The infection control cloud-based software platform solution enables “precision epidemiology” integrating pathogen genomics with clinical and patient demographics to improve patient outcomes and enhance the capability of the health system for infection control and surveillance.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的广播公司影响/商业潜力将是一个使用高级生物技术和数据分析的用户友好且可扩展的感染控制监视软件平台，以监视COVID-19的大流行。 COVID-19大流行强调了对快速测试，分析和跟踪的需求。该创新为医疗机构提供了下一代序列技术的访问，以及将医院级别数据与微生物信息集成和共享的集中式系统，以在任何地理范围内共享。该平台可以自动对细菌和病毒数据的分析，从而通过交互式Web界面为简化和临床相关的结果。提出的技术为临床医生和其他专家提供了重要的数据。该SBIR I期项目的智力优点是为临床医生提供最大的SARS-COV-2整个基因组集合，以供临床医生迅速检验医学假设，以进行诊断和处方性使用。我们的项目具有三个主要目标：1）合并自动分析管道以处理SARS-COV-2感染菌株的整个基因组； 2）与患者微生物组和临床记录进行整合的病毒基因组，以及； 3）通过交互式Web界面提供清晰，易于解释的结果。感染控制基于云的软件平台解决方案可以使“精确流行病学”与临床和患者人口统计相结合，以改善患者的结果并增强卫生系统在感染控制和监视的能力上。这奖反映了NSF的法规任务，并认为通过基金会的知识优点和广泛的crietia crietia crietia crietia crietia crietia crietia criter critia criteria crietia crietia crietia criteria criteria crietia crietia crietia crietia criperia criperia criperia awectia奖。